Impact of RUTF on Body Composition, Anemia and Zinc Status of PLWHA (PLWHA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02433743|
Recruitment Status : Completed
First Posted : May 5, 2015
Last Update Posted : May 5, 2015
|Condition or disease||Intervention/treatment||Phase|
|HIV-infection/Aids Malnutrition||Dietary Supplement: Ready-to-use therapeutic food (RUTF)||Not Applicable|
The sample size of the study (n=17 in each group) was calculated takin into account the mean gain of fat free mass (2.3± 2.1 kg) obtained in a study of PLWH supplemented with 43 g of RUTF/day. The randomization was performed upon admission using a computer-generated random number list (EPI INFO 6.0; Centers for Disease Control and Prevention, Atlanta).
Dietary intakes were measured during 7 consecutive days in 10 subjects of each group during the hospitalization period. Each meal served was weighed with a food scale (i-Balance 2600 Myweigh, Phoenix, USA).
Anthropometrics measurement was performed using standard procedures. Measure of height was made using height board (SECA 216, GmbH et Co, Hamburg, Germany), to the nearest millimeter. Body weight was measured with an electronic scale (SECA 877, GmbH & Co, Hamburg, Germany).
Body composition was measured using a multifrequency analyser, Xitron 4000B. The accuracy of the instrument was tested before the measurements by using a 422 ohm standard resistor purchased with the analyzer. Blood sampling was performed in the morning between 8 -10 AM into trace element-free polyethylene tubes zinc-free containing lithium heparin anticoagulant. The time of the sample collection and of the most recent food or milk intake were noted and used to adjust for this interval in the analysis of data. All the parameters were mesured in duplicate on admission, at 3 weeks and 9 weeks home based follup up.
Double entry data, and quality control of the entry were performed using Epi-Info version 3.5.1 (CDC, Atlanta, USA) and access. Statistical analysis was performed by Excel 2003 (Microsoft Corporation, Redmond, USA) and STATA / SE 11.0 (Stata Corporation, Texas, and USA). Results are expressed as mean ± standard deviation and percentage. PZ concentration was adjusted for the time interval between the last meal and the blood drawing to minimize the variability due to the known meal-related effects on PZ concentration and from infections/inflammation . Zinc deficiency was defined according to IZINCG cut-off. ANOVA followed by post-hoc Bonferroni tests for pairwise comparison of means or Student's t-test were also used on dependent measures. The Pearson Chi2 test or Fisher's exact test were used to compare percentages. P values 0.05 were considered as significant.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||65 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Daily Consumption of Ready-to-use Peanut-based Therapeutic Food Increased Fat Free Mass, Improved Anemia Status But Has no Impact on Zinc Status of People Living With HIV/AIDS (PLWHA)|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||July 2012|
No Intervention: Control
Control group (n=33) didn't received intervention. The received the standard hospital diet
Experimental: Ready-to-use therapeutic food (RUTF)
RUTF group (n=32) received the standard hospital diet combined with 100 g/day of RUTF
Dietary Supplement: Ready-to-use therapeutic food (RUTF)
HIV-infected patients were randomly allocated to receive standard hospital diet (Control: n=33), or this diet combined with 100 g/day of RUTF (RUTF: n=32). All patients was follow-up during hospitalisation and 9 week after discharge at home
Other Name: RUTF
- Change from baseline in body composition at 9 weeks [ Time Frame: 9 weeks ]Body composition was measured using Bio-impedance analysis method at baseline, and 9 weeks home-based follow-up in both supplemented and control groups
- Change from baseline on anemia at 3 weeks [ Time Frame: 3 weeks ]Hemoglobin was measured by Hemocue photometer at baseline and 3 week after admission in both supplemented and control groups
- Change from baseline on anemia at 9 weeks [ Time Frame: 9 weeks ]Hemoglobin was measured by Hemocue photometer at baseline and after 9 weeks home-based follow-up in both supplemented and control groups
- Change from baseline on plasma zinc concentration at 3 weeks [ Time Frame: 3 weeks ]Plasma zinc concentration was determined by Atomic absorption spectrometry at baseline and 3 weeks after admission in both supplemented and control groups
- Change from baseline on plasma zinc concentration at 9 weeks [ Time Frame: 9 weeks ]Plasma zinc concentration was determined by Atomic absorption spectrometry at baseline and after 9 weeks home-based follow-up in both supplemented and control groups
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02433743
|University Cheikh Anta Diop|
|Study Director:||Salimata Wade, Professor||Université Cheikh Anta Diop de Dakar|